The Board of Directors of Novozymes has appointed Peder Holk Nielsen as President and Chief Executive Officer with effect from April 1, 2013. Mr. Nielsen will replace the current President and CEO Steen Riisgaard who after 12 years as CEO and 33 years in Novozymes and Novo Industri/Novo Nordisk steps down according to plan.
Mr. Nielsen, 56, is currently serving as Executive Vice President and Head of Enzyme Business, a position he has held since 2007. Mr. Nielsen’s career spans management positions in Novozymes and Novo Industri/Novo Nordisk across business development, R&D, quality management and sales & marketing. He holds a M.Sc. and Ph.D. in Chemical Engineering from the Technical University of Denmark, and a B.Com. in International Business Management from the Copenhagen Business School.
Andrew Fordyce will join the executive leadership team on April 1, 2013
From April 1, 2013 Novozymes will have a new executive leadership team. All Executive Vice Presidents of the current executive management team will continue and Andrew Fordyce, 49, will join them. Mr. Fordyce is currently Vice President, Sales and Customer Solutions. Since joining the company in 1993, he has held several positions in commercial operations, R&D and production in Denmark, Switzerland and the US. Mr. Fordyce holds a Ph.D. in Chemical Engineering from the University of Texas at Austin.
On April 1, 2013 the executive leadership team will have the following members with new areas of responsibility:
President & CEO Peder Holk Nielsen
Business Development: EVP Thomas Videbæk
Business Operations: EVP Andrew Fordyce
Supply Operations: EVP Thomas Nagy
Research & Development: EVP and CSO Per Falholt
Corporate Functions: EVP and CFO Benny D. Loft
|
Contact persons: Press and media: |
Investor Relations: |
|
René Tronborg (DK) Tel.: +45 3077 2274 Paige Donnelly (USA) Tel.: +1 919 2184501 |
Maarit Pokkinen (DK) Tel.: +45 3077 8682 Martin Riise (DK) Tel.: +45 3077 0738 Thomas Bomhoff (USA), Tel.: +1 919 6492565 DK Tel.: +45 3077 1226 |
